-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 22, GlaxoSmithKline China announced that China's State Drug Administration has approved Cinkelai® for the maintenance treatment of adult patients with chronic obstructive pulmonary disease characterized by insufficiently controlled elevated blood eosinophils.

Zhitongcaijing·12/22/2025 08:09:03
Listen to the news
On December 22, GlaxoSmithKline China announced that China's State Drug Administration has approved Cinkelai® for the maintenance treatment of adult patients with chronic obstructive pulmonary disease characterized by insufficiently controlled elevated blood eosinophils.